X
Finally, AZ claims a win with Imfinzi/tremelimumab cancer combo
https://pharmaphorum.com/news/finally-az-claims-a-win-with-imfinzi-tremelimumab-cancer-combo/
Imfinzi
Groundbreaking lung cancer approval a big boost for AZ’s Imfinzi
AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.
AstraZeneca spies an upturn at last in 2018
AstraZeneca (AZ) will see growth in its revenues once again in 2018, after several years of decline caused by blockbuster expiries.
Interview: AZ’s immunotherapy gamble starts to pay off
Robert Iannone, AstraZeneca’s head of immune-oncology research, on the unpredictable immunotherapy market.